Global Assessment Of Disease Activity Research Articles

THU0444 Assessment of Global Disease Activity in RA by Patients and Physicians: Cultural Differences across Countries in the Meteor Database

BackgroundDissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global disease activity assessment (PtGDA and PhGDA,...

AB0760 Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: an Analysis from the Prospective, Observational Registry, Biotrac

BackgroundA definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the 7 following criteria: tender joint count...

FRI0138 A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis

BackgroundIn peripheral spondyloarthritis (pSpA), no specific efficacy endpoint has been developed representing improvement in arthritis, enthesitis, and/or dactylitis.ObjectivesTo assess the discriminatory aspects of disease activity measures and response criteria between...

FRI0142 Patient-Reported Disease Activity and Outcome in Male versus Female Patients of the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort

BackgroundThere are differences in clinical presentation of ankylosing spondylitis (AS). Women tend to have milder disease and may therefore be underdiagnosed. Male AS patients are more likely to develop spinal...

FRI0101 Assessing the Impact of BIOLOGICS Treatment on Use of Mechanical Devices/Aids by Rheumatoid Arthritis (RA) Patients Using A Large US Patient Registry

BackgroundSignificant improvements in disease activity and long term physical function have been documented following approval of biologic therapies for treatment of RA since 1998 [1, 2].ObjectivesTo determine if fewer RA...

SAT0071 Assessment of Rheumatoid Arthritis Disease Activity by Patients and Physicians: do Physicians Detect Improvement before the Patient Does?

ObjectivesPatient (PtGA) and physician (MDGA) global assessment of disease activity measure the same construct from two different perspectives. The objective of this study was to assess the agreement between these...

FRI0556 A Multi-Biomarker Disease Activity Blood Test in Patients with Juvenile Idiopathic Arthritis

BackgroundCurrent measures of disease activity for juvenile idiopathic arthritis (JIA), including physician global assessment of disease activity and active joint count, are subjective and potentially confounded by disease heterogeneity and...

SAT0083 Does Specific Joint Involvement in Rheumatoid Arthritis Patients PREDICT Patient Reported Outcomes? Implications for Clinical Practice

BackgroundAssessment of functional (dis)ability in rheumatoid arthritis (RA) is subject to patient judgment when appraising their ability to do daily activities.ObjectivesThe aim of this analysis was to describe the impact...

THU0438 Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?

BackgroundPatient (PtGA) and physician (MDGA) global assessment of disease activity are standard outcome measures used in clinical practice and research to ascertain patient and physician subjective perception of disease activity...

SAT0363 Validation of the Ankylosing Spondylitis Disease Activity SCORE (ASDAS) and Effectiveness of Infliximab in the Treatment of Ankylosing Spondylitis over 4 Years

ObjectivesTo assess in a clinical practice the 4-year outcomes in patients with AS treated with infliximab and the performance of ASDAS, a new disease activity measure in AS.MethodsBioTRAC is an...

AB0405 Baseline Predictors of Remission Rates during Golimumab Treatment for Rheumatoid Arthritis in the GO-MORE Study

BackgroundIn patients with rheumatoid arthritis (RA), current treatment strategies aim for clinical remission. Knowing which patients are likely to respond to biologic treatment is helpful when considering treatment options.ObjectivesTo evaluate...

AB0287 Are ALL Parameters of Disease Activity Score Reliable for Assessing Activity of Rheumatoid Arthritis in Tunisian Patients?

BackgroundRheumatoid arthritis (RA) is an inflammatory chronic disease with varying signs and outcomes. A valid, reliable and sensitive assessment tool that is able to assess activity is essential in clinical...

AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis?

BackgroundThe prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men. Furthermore, RA incidence in women increases from the age of menarche peaking around menopause, while...

AB0286 Ultrasound Defined Remission in Tunisian Rheumatoid Arthritis

BackgroundRemission is the principal purpose of treatment in rheumatoid arthritis (RA). Different scores and indices are available to define remission. However, even when the most stringent ones are used, structural...

FRI0047 Prediction of Remission by Patients and Physicians: Does the Doctor Know Best?

BackgroundPatient (PtGA) and physician (MDGA) assessment of global disease activity have been used as outcome measures individually or as part of composite scores in the measurement of rheumatoid arthritis (RA)...

OP0156 Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-Of-Concept Study with Nilotinib A Tyrosine Kinase Inhibitor

BackgroundImmunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting the signalling of c-Kit, which is...

THU0155 Predictors of Low Disease Activity and Remission after One Dose of Golimumab in Patients with Rheumatoid Arthritis

BackgroundPatients with rheumatoid arthritis (RA) who respond well to biologics early in treatment tend to have better outcomes. Identifying baseline characteristics that predict early response may facilitate effective patient segmentation...

THU0423 The Impact of Etanercept and Methotrexate Treatment on Work Productivity in Patients with Rheumatoid Arthritis: Results from Phase 2 of the Prize Study

BackgroundRecent studies have demonstrated that biologic agents can improve work productivity in patients with rheumatoid arthritis (RA). However, the long term consequences on work productivity, particularly in step down treatment...

OP0047 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis

BackgroundInterleukin-6 is a pro-inflammatory cytokine that is over-expressed in LN.ObjectivesThis proof-of-concept study examined the efficacy and safety of sirukumab, an anti-interleukin-6 monoclonal antibody, in patients (pts) with active, ISN/RPS class...

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

ObjectiveTo describe clinical outcomes of juvenile idiopathic arthritis (JIA) in a prospective inception cohort of children managed with contemporary treatments.MethodsChildren newly diagnosed with JIA at 16 Canadian paediatric rheumatology centres...